Glucagon (19-29), human
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
Product Specifications
CAS Number
64790-15-4
UNSPSC
12352209
Target
GCGR
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Glucagon__19-29_,_human.html
Purity
99.11
Solubility
DMSO : ≥ 25 mg/mL|H2O : 1.25 mg/mL (ultrasonic; adjust pH to 9 with NH3·H2O)
Smiles
O=C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)=O)=O)[C@@H](NC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@@H](NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)C)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)CC2=CNC3=C2C=CC=C3
Molecular Formula
C61H89N15O18S
Molecular Weight
1352.53
References & Citations
[1]Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274 (16) :10869-76.|[2]Dalle S, et al. Miniglucagon (glucagon 19-29) : a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51 (2) :406-12.|[3]Pavoine C, et al. Miniglucagon [glucagon- (19-29) ] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260 (5 Pt 1) :C993-9.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC882715-100 1x 100 µL
PAPP-A / Pappalysin-1 (Marker of Atherosclerosis and Aneuploid Fetus) (PAPPA/2715), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
